155 related articles for article (PubMed ID: 2876570)
1. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor.
Wilson DM; Hoffman AR
Acta Endocrinol (Copenh); 1986 Sep; 113(1):23-8. PubMed ID: 2876570
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: characterization and quantification of plasma and tumor human growth hormone-releasing factor.
Wilson DM; Ceda GP; Bostwick DG; Webber RJ; Minkoff JR; Pont A; Hintz RL; Bensch KG; Kraemer FB; Rosenfeld RG
J Clin Endocrinol Metab; 1984 Nov; 59(5):1002-5. PubMed ID: 6090497
[TBL] [Abstract][Full Text] [Related]
3. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
Thorner MO; Perryman RL; Cronin MJ; Rogol AD; Draznin M; Johanson A; Vale W; Horvath E; Kovacs K
J Clin Invest; 1982 Nov; 70(5):965-77. PubMed ID: 6290540
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long-acting somatostatin analogue SMS 201-995.
Barkan AL; Shenker Y; Grekin RJ; Vale WW
Cancer; 1988 Jan; 61(2):221-6. PubMed ID: 2891432
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
7. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly.
Bloom SR
Am J Med; 1987 May; 82(5B):88-91. PubMed ID: 2884882
[TBL] [Abstract][Full Text] [Related]
9. Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects.
Losa M; Müller OA; Sobieszczyk S; von Werder K
Clin Endocrinol (Oxf); 1985 Dec; 23(6):715-20. PubMed ID: 2869845
[TBL] [Abstract][Full Text] [Related]
10. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor.
Melmed S; Ziel FH; Braunstein GD; Downs T; Frohman LA
J Clin Endocrinol Metab; 1988 Aug; 67(2):395-9. PubMed ID: 2899089
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
12. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly.
Pieters GF; Smals AE; Smals AG; von Gennep JA; Kloppenborg PW
Acta Endocrinol (Copenh); 1987 Apr; 114(4):537-42. PubMed ID: 2883797
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
17. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
18. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor.
Ezzat S; Ezrin C; Yamashita S; Melmed S
Cancer; 1993 Jan; 71(1):66-70. PubMed ID: 8416728
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly due to ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumour. Dynamic hormonal responses to various stimuli.
Glikson M; Gil-Ad I; Galun E; Dresner R; Zilberman S; Halperin Y; Okon E; Laron Z; Rubinow A
Acta Endocrinol (Copenh); 1991 Oct; 125(4):366-71. PubMed ID: 1683501
[TBL] [Abstract][Full Text] [Related]
20. Morphology of a GHRH producing pancreatic islet cell tumour causing acromegaly.
Saeger W; Schulte HM; Klöppel G
Virchows Arch A Pathol Anat Histopathol; 1986; 409(4):547-54. PubMed ID: 3016979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
